Guido Sauter

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/6713942/publications.pdf

Version: 2024-02-01

253	13,109	71102	26613
papers	citations	41 h-index	107 g-index

257	257	257	15170
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cytokeratin 5 and cytokeratin 6 expressions are unconnected in normal and cancerous tissues and have separate diagnostic implications. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2022, 480, 433-447.	2.8	11
2	CHD1 loss negatively influences metastasis-free survival in R0-resected prostate cancer patients and promotes spontaneous metastasis in vivo. Cancer Gene Therapy, 2022, 29, 49-61.	4.6	3
3	Carboxypeptidase A1 (CPA1) Immunohistochemistry Is Highly Sensitive and Specific for Acinar Cell Carcinoma (ACC) of the Pancreas. American Journal of Surgical Pathology, 2022, 46, 97-104.	3.7	18
4	Semi-automated validation and quantification of CTLA-4 in 90 different tumor entities using multiple antibodies and artificial intelligence. Laboratory Investigation, 2022, 102, 650-657.	3.7	5
5	Abstract P068: Automated cell type specific PD-L1 quantification by artificial intelligence using high throughput bleach & stain 15-marker multiplex fluorescence immunohistochemistry in human cancers. , 2022, , .		0
6	Abstract P069: Semi-automated validation and quantification of CTLA-4 in 90 different Tumor entities using multiple antibodies and artificial intelligence. , 2022, , .		0
7	Combination of Biochemical and Cytological Findings for Better Diagnosis in Pleural Effusions. Advances in Experimental Medicine and Biology, 2022, , 51.	1.6	1
8	VPRBP Functions Downstream of the Androgen Receptor and OGT to Restrict p53 Activation in Prostate Cancer. Molecular Cancer Research, 2022, 20, 1047-1060.	3.4	2
9	PITX1 Is a Regulator of TERT Expression in Prostate Cancer with Prognostic Power. Cancers, 2022, 14, 1267.	3.7	7
10	Cytokeratin 7 and cytokeratin 20 expression in cancer: A tissue microarray study on 15,424 cancers. Experimental and Molecular Pathology, 2022, 126, 104762.	2.1	15
11	Trophoblast Cell Surface Antigen 2 Expression in Human Tumors: A Tissue Microarray Study on 18,563 Tumors. Pathobiology, 2022, 89, 245-258.	3.8	15
12	Large-scale human tissue analysis identifies Uroplakin 1b as a putative diagnostic marker in surgical pathology. Human Pathology, 2022, 126, 108-120.	2.0	4
13	Immune phenotypes and T-cell density at the invasive margin correlate with prognosis in epithelial vulvar cancer.. Journal of Clinical Oncology, 2022, 40, 5599-5599.	1.6	0
14	Mucin 5AC expression is common but unrelated to tumor progression in pancreatic adenocarcinoma. International Journal of Immunopathology and Pharmacology, 2022, 36, 039463202211065.	2.1	1
15	High level of EZH2 expression is linked to high density of CD8-positive T-lymphocytes and an aggressive phenotype in renal cell carcinoma. World Journal of Urology, 2021, 39, 481-490.	2.2	11
16	A non-diploid DNA status is linked to poor prognosis in renal cell cancer. World Journal of Urology, 2021, 39, 829-837.	2.2	3
17	Prostate cancer grading, time to go back to the future. BJU International, 2021, 127, 165-168.	2.5	4
18	MUC5AC Expression in Various Tumor Types and Nonneoplastic Tissue: A Tissue Microarray Study on 10â€…399 Tissue Samples. Technology in Cancer Research and Treatment, 2021, 20, 153303382110433.	1.9	10

#	Article	IF	Citations
19	Reduced anoctamin 7 (ANO7) expression is a strong and independent predictor of poor prognosis in prostate cancer. Cancer Biology and Medicine, 2021, 18, 245-255.	3.0	13
20	p63 expression in human tumors and normal tissues: a tissue microarray study on 10,200 tumors. Biomarker Research, 2021, 9, 7.	6.8	33
21	Opposing prognostic relevance of junction plakoglobin in distinct prostate cancer patient subsets. Molecular Oncology, 2021, 15, 1956-1969.	4.6	5
22	Diagnostic and prognostic impact of cytokeratin 18 expression in human tumors: a tissue microarray study on 11,952 tumors. Molecular Medicine, 2021, 27, 16.	4.4	32
23	Y-chromosome loss is frequent in male renal tumors. Annals of Translational Medicine, 2021, 9, 209-209.	1.7	13
24	Mismatch repair deficiency occurs very rarely in seminomas. Translational Andrology and Urology, 2021, 10, 1048-1055.	1.4	3
25	Napsin A Expression in Human Tumors and Normal Tissues. Pathology and Oncology Research, 2021, 27, 613099.	1.9	12
26	Tumor cell PD-L1 expression is a strong predictor of unfavorable prognosis in immune checkpoint therapy-naive clear cell renal cell cancer. International Urology and Nephrology, 2021, 53, 2493-2503.	1.4	11
27	Mesothelin Expression in Human Tumors: A Tissue Microarray Study on 12,679 Tumors. Biomedicines, 2021, 9, 397.	3.2	42
28	Prognostic markers in pT3 bladder cancer: A study from the international bladder cancer tissue microarray project. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 301.e17-301.e28.	1.6	7
29	E-Cadherin expression in human tumors: a tissue microarray study on 10,851 tumors. Biomarker Research, 2021, 9, 44.	6.8	30
30	Increased lysophosphatidylcholine acyltransferase 1 expression is unrelated to prognosis of esophageal cancer patients. Journal of Cancer Research and Clinical Oncology, 2021, 147, 2879-2884.	2.5	1
31	High density of cytotoxic T-lymphocytes is linked to tumoral PD-L1 expression regardless of the mismatch repair status in colorectal cancer. Acta OncolÃ³gica, 2021, 60, 1210-1217.	1.8	10
32	Abstract 2735: Clinical significance of CD4+CD7â˜helper T-cells and tumoral CD7 expression in colorectal cancer. , 2021, , .		0
33	Abstract 2833: Mesothelin expression in human tumor types: a tissue microarray study on more than 13,000 tumor samples. , 2021, , .		0
34	Abstract 2773: Deep profiling of the PD-1/PD-L1 pathway in 10000 cancers revealed changes in the immune cell composition between cancer entities. , 2021, , .		0
35	Abstract 2775: PD-L1 expression in human tumors: a tissue microarray study on 5,561 tissue samples and 87 tumor types. , 2021, , .		0
36	Abstract 2750: Prognostic impact of tumor infiltrating lymphocytes in the tumor microenvironment of vulvar squamous cell carcinoma. , 2021, , .		0

#	Article	IF	Citations
37	High mitochondrial content is associated with breast cancer aggressiveness. Molecular and Clinical Oncology, 2021, 15, 203.	1.0	3
38	DOG1 is commonly expressed in pancreatic adenocarcinoma but unrelated to cancer aggressiveness. PeerJ, 2021, 9, e11905.	2.0	4
39	Pattern of placental alkaline phosphatase (<scp>PLAP</scp>) expression in human tumors: a tissue microarray study on 12,381 tumors. Journal of Pathology: Clinical Research, 2021, 7, 577-589.	3.0	12
40	Diagnostic and prognostic impact of cytokeratin 19 expression analysis in human tumors: a tissue microarray study of 13,172 tumors. Human Pathology, 2021, 115, 19-36.	2.0	19
41	Recommendations for immunocytochemistry in lung cancer typing: An update on a resourceâ€efficient approach with largeâ€scale comparative Bayesian analysis. Cytopathology, 2021, , .	0.7	2
42	Immunohistochemically detectable thyroglobulin expression in extrathyroidal cancer is 100% specific for thyroidal tumor origin. Annals of Diagnostic Pathology, 2021, 54, 151793.	1.3	11
43	Elevated MUC5AC expression is associated with mismatch repair deficiency and proximal tumor location but not with cancer progression in colon cancer. Medical Molecular Morphology, 2021, 54, 156-165.	1.0	9
44	DOG1 expression is common in human tumors: A tissue microarray study on more than 15,000 tissue samples. Pathology Research and Practice, 2021, 228, 153663.	2.3	11
45	6q deletion is frequent but unrelated to patient prognosis in breast cancer. Breast Cancer, 2021, , 1.	2.9	1
46	Cytological Diagnostic Procedures in Malignant Mesothelioma. Advances in Experimental Medicine and Biology, 2021, , 41-49.	1.6	3
47	Large-Scale Tissue Microarray Evaluation Corroborates High Specificity of High-Level Arginase-1 Immunostaining for Hepatocellular Carcinoma. Diagnostics, 2021, 11, 2351.	2.6	2
48	Angiotensin-Converting Enzyme 2 Protein Is Overexpressed in a Wide Range of Human Tumour Types: A Systematic Tissue Microarray Study on >15,000 Tumours. Biomedicines, 2021, 9, 1831.	3.2	7
49	Biperiden and mepazine effectively inhibit MALT1 activity and tumor growth in pancreatic cancer. International Journal of Cancer, 2020, 146, 1618-1630.	5.1	12
50	Loss of cytoplasmic survivin expression is an independent predictor of poor prognosis in radically operated prostate cancer patients. Cancer Medicine, 2020, 9, 1409-1418.	2.8	5
51	Expression of CCCTCâ€binding factor (CTCF) is linked to poor prognosis in prostate cancer. Molecular Oncology, 2020, 14, 129-138.	4.6	19
52	High homogeneity of mismatch repair deficiency in advanced prostate cancer. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 476, 745-752.	2.8	17
53	High-grade intratumoral tumor budding is a predictor for lymphovascular invasion and adverse outcome in stage II colorectal cancer. International Journal of Colorectal Disease, 2020, 35, 259-268.	2.2	17
54	8p deletions in renal cell carcinoma are associated with unfavorable tumor features and poor overall survival. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 43.e13-43.e20.	1.6	8

#	Article	IF	Citations
55	Claudin-1 upregulation is associated with favorable tumor features and a reduced risk for biochemical recurrence in ERG-positive prostate cancer. World Journal of Urology, 2020, 38, 2185-2196.	2.2	10
56	TIP5 primes prostate luminal cells for the oncogenic transformation mediated by PTEN -loss. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 3637-3647.	7.1	17
57	Secreted Frizzled-Related Protein 4 (SFRP4) Is an Independent Prognostic Marker in Prostate Cancers Lacking TMPRSS2: ERG Fusions. Pathology and Oncology Research, 2020, 26, 2709-2722.	1.9	7
58	Ectopic Expression of Hematopoietic SHIP1 in Human Colorectal Cancer. Biomedicines, 2020, 8, 215.	3.2	2
59	Increased Cytoplasmic CD138 Expression Is Associated with Aggressive Characteristics in Prostate Cancer and Is an Independent Predictor for Biochemical Recurrence. BioMed Research International, 2020, 2020, 1-13.	1.9	7
60	High B7â€H3 expression is linked to increased risk of prostate cancer progression. Pathology International, 2020, 70, 733-742.	1.3	16
61	Differential regulation of extracellular matrix proteins in three recurrent liver metastases of a single patient with colorectal cancer. Clinical and Experimental Metastasis, 2020, 37, 649-656.	3.3	4
62	Epithelial splicing regulatory protein 1 and 2 (ESRP1 and ESRP2) upregulation predicts poor prognosis in prostate cancer. BMC Cancer, 2020, 20, 1220.	2.6	12
63	Upregulation of Phosphatase 1 Nuclear-Targeting Subunit (PNUTS) Is an Independent Predictor of Poor Prognosis in Prostate Cancer. Disease Markers, 2020, 2020, 1-10.	1.3	4
64	Upregulation of the heterogeneous nuclear ribonucleoprotein hnRNPA1 is an independent predictor of early biochemical recurrence in TMPRSS2:ERG fusion-negative prostate cancers. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2020, 477, 625-636.	2.8	6
65	A pre-specified model based on four kallikrein markers in blood improves predictions of adverse pathology and biochemical recurrence after radical prostatectomy. British Journal of Cancer, 2020, 123, 604-609.	6.4	9
66	Chromosome 17p13 deletion is associated with an aggressive tumor phenotype in clear cell renal cell carcinoma. World Journal of Surgical Oncology, 2020, 18, 128.	1.9	3
67	Upregulation of the transcription factor TFAP2D is associated with aggressive tumor phenotype in prostate cancer lacking the TMPRSS2:ERG fusion. Molecular Medicine, 2020, 26, 24.	4.4	5
68	Loss of the adhesion molecule CEACAM1 is associated with early biochemical recurrence in TMPRSS2:ERG fusionâ€positive prostate cancers. International Journal of Cancer, 2020, 147, 575-583.	5.1	4
69	Prevalence of CD8+ cytotoxic lymphocytes in human neoplasms. Cellular Oncology (Dordrecht), 2020, 43, 421-430.	4.4	23
70	Homogeneous MMR Deficiency Throughout the Entire Tumor Mass Occurs in a Subset of Colorectal Neuroendocrine Carcinomas. Endocrine Pathology, 2020, 31, 182-189.	9.0	15
71	MMR Deficiency is Homogeneous in Pancreatic Carcinoma and Associated with High Density of Cd8-Positive Lymphocytes. Annals of Surgical Oncology, 2020, 27, 3997-4006.	1.5	20
72	IL22BP Mediates the Antitumor Effects of Lymphotoxin Against Colorectal Tumors in Mice and Humans. Gastroenterology, 2020, 159, 1417-1430.e3.	1.3	31

#	Article	IF	Citations
73	Reduced KLK2 expression is a strong and independent predictor of poor prognosis in ERGâ€negative prostate cancer. Prostate, 2020, 80, 1097-1107.	2.3	10
74	Subcellular Compartmentalization of Survivin is Associated with Biological Aggressiveness and Prognosis in Prostate Cancer. Scientific Reports, 2020, 10, 3250.	3.3	18
75	MMR deficiency in urothelial carcinoma of the bladder presents with temporal and spatial homogeneity throughout the tumor mass. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 488-495.	1.6	19
76	Extreme intratumour heterogeneity and driver evolution in mismatch repair deficient gastro-oesophageal cancer. Nature Communications, 2020, 11, 139.	12.8	44
77	High homogeneity of MMR deficiency in ovarian cancer. Gynecologic Oncology, 2020, 156, 669-675.	1.4	24
78	High CHK2 protein expression is a strong and independent prognostic feature in ERG negative prostate cancer. Pathology, 2020, 52, 421-430.	0.6	5
79	Chromosomal deletion of 9p21 is linked to poor patient prognosis in papillary and clear cell kidney cancer. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 605.e1-605.e8.	1.6	3
80	Upregulation of PTTG1 is associated with poor prognosis in prostate cancer. Pathology International, 2020, 70, 441-451.	1.3	8
81	Prevalence and clinical significance of VHL mutations and 3p25 deletions in renal tumor subtypes. Oncotarget, 2020, 11, 237-249.	1.8	19
82	Loss of p16 and high Ki67 labeling index is associated with poor outcome in esophageal carcinoma. Oncotarget, 2020, 11, 1007-1016.	1.8	14
83	Web-based Prostate Visualization Tool. Current Directions in Biomedical Engineering, 2020, 6, 563-566.	0.4	0
84	Down-Regulation of S100A8 is an Independent Predictor of PSA Recurrence in Prostate Cancer Treated by Radical Prostatectomy. Neoplasia, 2019, 21, 872-881.	5.3	5
85	Expression of the immune checkpoint receptor TIGIT in seminoma. Oncology Letters, 2019, 18, 1497-1502.	1.8	7
86	The independent prognostic impact of the GATA2 pioneering factor is restricted to ERG-negative prostate cancer. Tumor Biology, 2019, 41, 101042831882481.	1.8	9
87	High-level expression of protein tyrosine phosphatase non-receptor 12 is a strong and independent predictor of poor prognosis in prostate cancer. BMC Cancer, 2019, 19, 944.	2.6	4
88	Selectin Binding Sites Are Involved in Cell Adhesive Properties of Head and Neck Squamous Cell Carcinoma. Cancers, 2019, 11, 1672.	3.7	7
89	Random forest-based modelling to detect biomarkers for prostate cancer progression. Clinical Epigenetics, 2019, 11, 148.	4.1	89
90	The impact of variant histological differentiation on extranodal extension and survival in node positive bladder cancer treated with radical cystectomy. Surgical Oncology, 2019, 28, 208-213.	1.6	14

#	Article	IF	Citations
91	Current Therapies of Wilms Tumors in the Adult: Diagnostic Considerations and Treatment Challenges. Clinical Genitourinary Cancer, 2019, 17, e522-e525.	1.9	1
92	Loss of PSP94 expression is associated with early PSA recurrence and deteriorates outcome of PTEN deleted prostate cancers. Cancer Biology and Medicine, 2019, 16, 319.	3.0	2
93	Hyperparameter optimization for image analysis: application to prostate tissue images and live cell data of virus-infected cells. International Journal of Computer Assisted Radiology and Surgery, 2019, 14, 1847-1857.	2.8	6
94	Immune Exclusion Is Frequent in Small-Cell Carcinoma of the Bladder. Disease Markers, 2019, 2019, 1-6.	1.3	12
95	SNW1 is a prognostic biomarker in prostate cancer. Diagnostic Pathology, 2019, 14, 33.	2.0	7
96	p53 overexpression is a prognosticator of poor outcome in esophageal cancer. Oncology Letters, 2019, 17, 3826-3834.	1.8	19
97	Response to olaparib in a PALB2 germline mutated prostate cancer and genetic events associated with resistance. Journal of Physical Education and Sports Management, 2019, 5, a003657.	1.2	36
98	Aberrant expression of the microtubule-associated protein tau is an independent prognostic feature in prostate cancer. BMC Cancer, 2019, 19, 193.	2.6	24
99	Prevalence of Syndecan-1 (CD138) Expression in Different Kinds of Human Tumors and Normal Tissues. Disease Markers, 2019, 2019, 1-11.	1.3	38
100	Loss of CCAATâ€enhancerâ€binding protein alpha (CEBPA) is linked to poor prognosis in PTEN deleted and TMPRSS2:ERG fusion type prostate cancers. Prostate, 2019, 79, 302-311.	2.3	4
101	5q21 deletion is often heterogeneous in prostate cancer. Genes Chromosomes and Cancer, 2019, 58, 509-515.	2.8	4
102	Survivin expression in head and neck squamous cell carcinomas is frequent and correlates with clinical parameters and treatment outcomes. Clinical Oral Investigations, 2019, 23, 361-367.	3.0	8
103	Up-regulation of lysophosphatidylcholine acyltransferase 1 (LPCAT1) is linked to poor prognosis in breast cancer. Aging, 2019, 11, 7796-7804.	3.1	33
104	Up regulation of Rho-associated coiled-coil containing kinase1 (ROCK1) is associated with genetic instability and poor prognosis in prostate cancer. Aging, 2019, 11, 7859-7879.	3.1	28
105	A nuclear shift of GSK3Î² protein is an independent prognostic factor in prostate cancer. Oncotarget, 2019, 10, 1729-1744.	1.8	2
106	Nuclear ELAC2 overexpression is associated with increased hazard for relapse after radical prostatectomy. Oncotarget, 2019, 10, 4973-4986.	1.8	5
107	Prognostic and diagnostic role of PSA immunohistochemistry: A tissue microarray study on 21,000 normal and cancerous tissues. Oncotarget, 2019, 10, 5439-5453.	1.8	22
108	Nuclear up regulation of the BRCA1-associated ubiquitinase BAP1 is associated with tumor aggressiveness in prostate cancers lacking the TMPRSS2:ERG fusion. Oncotarget, 2019, 10, 7096-7111.	1.8	4

#	Article	IF	Citations
109	Upregulation of SPDEF is associated with poor prognosis in prostate cancer. Oncology Letters, 2019, 18, 5107-5118.	1.8	9
110	IMP3 overexpression occurs in various important cancer types and is linked to aggressive tumor features: A tissue microarray study on 8,877 human cancers and normal tissues. Oncology Reports, 2018, 39, 3-12.	2.6	50
111	<scp>EZH</scp>2 overexpression in head and neck cancer is related to lymph node metastasis. Journal of Oral Pathology and Medicine, 2018, 47, 240-245.	2.7	16
112	High BCAR1 expression is associated with early PSA recurrence in ERG negative prostate cancer. BMC Cancer, 2018, 18, 37.	2.6	16
113	Immunohistochemically detected IDH1R132H mutation is rare and mostly heterogeneous in prostate cancer. World Journal of Urology, 2018, 36, 877-882.	2.2	26
114	Integrating Tertiary Gleason 5 Patterns into Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2018, 73, 674-683.	1.9	40
115	Prevalence of fibroblast growth factor receptor 1 (FGFR1) amplification in squamous cell carcinomas of the head and neck. Journal of Cancer Research and Clinical Oncology, 2018, 144, 53-61.	2.5	11
116	Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. Clinical Genitourinary Cancer, 2018, 16, e141-e149.	1.9	10
117	Deep Learning for Natural Language Processing in Urology: State-of-the-Art Automated Extraction of Detailed Pathologic Prostate Cancer Data From Narratively Written Electronic Health Records. JCO Clinical Cancer Informatics, 2018, 2, 1-9.	2.1	150
118	Upregulation of centromere protein F is linked to aggressive prostate cancers. Cancer Management and Research, 2018, Volume 10, 5491-5504.	1.9	17
119	High expression of class III Î²â€tubulin in upper gastrointestinal cancer types. Oncology Letters, 2018, 16, 7139-7145.	1.8	10
120	Expression of the immune checkpoint receptor TIGIT in Hodgkinâ€™s lymphoma. BMC Cancer, 2018, 18, 1209.	2.6	28
121	Reduced RBM3 expression is associated with aggressive tumor features in esophageal cancer but not significantly linked to patient outcome. BMC Cancer, 2018, 18, 1106.	2.6	9
122	Deletion of 3p13 is a late event linked to progression of TMPRSS2:ERG fusion prostate cancer. Cancer Management and Research, 2018, Volume 10, 5909-5917.	1.9	3
123	Molecular Evolution of Early-Onset Prostate Cancer Identifies Molecular Risk Markers and Clinical Trajectories. Cancer Cell, 2018, 34, 996-1011.e8.	16.8	190
124	Evaluating Guideline Adherence for T1 Bladder Cancer Treatment and Surveillance: A Retrospective German Multicenter Observation. Urologia Internationalis, 2018, 101, 285-292.	1.3	4
125	Aberrant expression of membranous carbonic anhydrase IX (CAIX) is associated with unfavorable disease course in papillary and clear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2018, 36, 531.e19-531.e25.	1.6	17
126	Identification of a High-Level MET Amplification in CTCs and cfTNA of an ALK-Positive NSCLC Patient Developing Evasive Resistance to Crizotinib. Journal of Thoracic Oncology, 2018, 13, e243-e246.	1.1	18

#	Article	IF	Citations
127	Up regulation of the steroid hormone synthesis regulator HSD3B2 is linked to early PSA recurrence in prostate cancer. Experimental and Molecular Pathology, 2018, 105, 50-56.	2.1	6
128	13q deletion is linked to an adverse phenotype and poor prognosis in prostate cancer. Genes Chromosomes and Cancer, 2018, 57, 504-512.	2.8	35
129	PSCA expression is associated with favorable tumor features and reduced PSA recurrence in operated prostate cancer. BMC Cancer, 2018, 18, 612.	2.6	19
130	CAIX furthers tumour progression in the hypoxic tumour microenvironment of esophageal carcinoma and is a possible therapeutic target. Journal of Enzyme Inhibition and Medicinal Chemistry, 2018, 33, 1024-1033.	5.2	15
131	Marked Prognostic Impact of Minimal Lymphatic Tumor Spread in Prostate Cancer. European Urology, 2018, 74, 376-386.	1.9	58
132	A pre-specified statistical model based on four kallikrein markers in blood to predict advanced pathology on radical prostatectomy.. Journal of Clinical Oncology, 2018, 36, 5073-5073.	1.6	0
133	Tumor volume improves the long-term prediction of biochemical recurrence-free survival after radical prostatectomy for localized prostate cancer with positive surgical margins. World Journal of Urology, 2017, 35, 199-206.	2.2	19
134	Î² III-tubulin overexpression is linked to aggressive tumor features and genetic instability in urinary bladder cancer. Human Pathology, 2017, 61, 210-220.	2.0	23
135	Apurinic/apyrimidinic endonuclease 1 (APE1/Refâ€1) overexpression is an independent prognostic marker in prostate cancer without TMPRSS2:ERG fusion. Molecular Carcinogenesis, 2017, 56, 2135-2145.	2.7	19
136	Androgen Receptor Deregulation Drives Bromodomain-Mediated Chromatin Alterations in Prostate Cancer. Cell Reports, 2017, 19, 2045-2059.	6.4	99
137	Overexpression of the A Disintegrin and Metalloproteinase ADAM15 is linked to a Small but Highly Aggressive Subset of Prostate Cancers. Neoplasia, 2017, 19, 279-287.	5.3	16
138	Highâ€Level Glyoxalase 1 (GLO1) expression is linked to poor prognosis in prostate cancer. Prostate, 2017, 77, 1528-1538.	2.3	16
139	Prevalence of Î²III-tubulin (TUBB3) expression in human normal tissues and cancers. Tumor Biology, 2017, 39, 101042831771216.	1.8	51
140	FOXA1 expression is a strong independent predictor of early PSA recurrence in ERG negative prostate cancers treated by radical prostatectomy. Carcinogenesis, 2017, 38, 1180-1187.	2.8	15
141	Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer. Neoplasia, 2017, 19, 707-715.	5.3	65
142	Mitochondrial mutations drive prostate cancer aggression. Nature Communications, 2017, 8, 656.	12.8	100
143	Highâ€level Î²<scp>III</scp>â€tubulin overexpression occurs in most head and neck cancers but is unrelated to clinical outcome. Journal of Oral Pathology and Medicine, 2017, 46, 986-990.	2.7	14
144	Quantification of telomere features in tumor tissue sections by an automated 3D imaging-based workflow. Methods, 2017, 114, 60-73.	3.8	15

#	Article	IF	Citations
145	HER2 Status in Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma for Entry to the TRIO-013/LOGiC Trial of Lapatinib. Molecular Cancer Therapeutics, 2017, 16, 228-238.	4.1	38
146	CD151 expression is frequent but unrelated to clinical outcome in head and neck cancer. Clinical Oral Investigations, 2017, 21, 1503-1508.	3.0	2
147	High-Level Î³-Glutamyl-Hydrolase (GGH) Expression is Linked to Poor Prognosis in ERG Negative Prostate Cancer. International Journal of Molecular Sciences, 2017, 18, 286.	4.1	30
148	Increased ERCC1 expression is linked to chromosomal aberrations and adverse tumor biology in prostate cancer. BMC Cancer, 2017, 17, 504.	2.6	9
149	Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer. Oncotarget, 2017, 8, 31494-31508.	1.8	10
150	PTEN loss detection in prostate cancer: comparison of PTEN immunohistochemistry and PTEN FISH in a large retrospective prostatectomy cohort. Oncotarget, 2017, 8, 65566-65576.	1.8	56
151	Deletion lengthening at chromosomes 6q and 16q targets multiple tumor suppressor genes and is associated with an increasingly poor prognosis in prostate cancer. Oncotarget, 2017, 8, 108923-108935.	1.8	26
152	Impact of the Ki-67 labeling index and p53 expression status on disease-free survival in pT1 urothelial carcinoma of the bladder. Translational Andrology and Urology, 2017, 6, 1018-1026.	1.4	12
153	Effect of mast cells on efficacy of anti-angiogenic therapy by secreting matrix-degrading granzyme b.. Journal of Clinical Oncology, 2017, 35, 11522-11522.	1.6	1
154	Expression of Epithelialâ˜'Mesenchymal Transition Regulating Transcription Factors in Head and Neck Squamous Cell Carcinomas. , 2017, 37, 5435-5440.		9
155	Cyclin D1 gene amplification is highly homogeneous in breast cancer. Breast Cancer, 2016, 23, 111-119.	2.9	33
156	Cytoplasmic accumulation of ELAVL1 is an independent predictor of biochemical recurrence associated with genomic instability in prostate cancer. Prostate, 2016, 76, 259-272.	2.3	27
157	Diverse expression patterns of the <scp>EMT</scp> suppressor grainyheadâ€like 2 (<scp>GRHL</scp>2) in normal and tumour tissues. International Journal of Cancer, 2016, 138, 949-963.	5.1	18
158	The Combination of DNA Ploidy Status and PTEN/6q15 Deletions Provides Strong and Independent Prognostic Information in Prostate Cancer. Clinical Cancer Research, 2016, 22, 2802-2811.	7.0	21
159	p16 upregulation is linked to poor prognosis in ERG negative prostate cancer. Tumor Biology, 2016, 37, 12655-12663.	1.8	20
160	Heterogeneity of ERG expression in prostate cancer: a large section mapping study of entire prostatectomy specimens from 125 patients. BMC Cancer, 2016, 16, 641.	2.6	24
161	Reduced <scp>AZGP1</scp> expression is an independent predictor of early <scp>PSA</scp> recurrence and associated with ERGâ€fusion positive and <scp>PTEN</scp> deleted prostate cancers. International Journal of Cancer, 2016, 138, 1199-1206.	5.1	30
162	The zinc-finger transcription factor SALL4 is frequently expressed in human cancers: association with clinical outcome in squamous cell carcinoma but not in adenocarcinoma of the esophagus. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 483-492.	2.8	14

#	Article	IF	Citations
163	Internal standardization of LA-ICP-MS immuno imaging via printing of universal metal spiked inks onto tissue sections. Journal of Analytical Atomic Spectrometry, 2016, 31, 801-808.	3.0	26
164	Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers. Pathology and Oncology Research, 2016, 22, 95-102.	1.9	19
165	Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. European Urology, 2016, 69, 592-598.	1.9	212
166	Aquaporin 5 expression is frequent in prostate cancer and shows a dichotomous correlation with tumor phenotype and PSA recurrence. Human Pathology, 2016, 48, 102-110.	2.0	18
167	High Ki67 expression is an independent good prognostic marker in colorectal cancer. Journal of Clinical Pathology, 2016, 69, 209-214.	2.0	114
168	Tissue Microarrays. Methods in Molecular Biology, 2016, 1381, 53-65.	0.9	37
169	E-selectin ligand binding affinity to determine anti-metastatic efficacy of proteasome inhibition.. Journal of Clinical Oncology, 2016, 34, e23010-e23010.	1.6	1
170	p16 overexpression and 9p21 deletion are linked to unfavorable tumor phenotype in breast cancer. Oncotarget, 2016, 7, 81322-81331.	1.8	31
171	Heterogeneity and chronology of 6q15 deletion and ERG-fusion in prostate cancer. Oncotarget, 2016, 7, 3897-3904.	1.8	8
172	HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.. Journal of Clinical Oncology, 2016, 34, 515-515.	1.6	1
173	The polyphosphateâ€“factor XII pathway drives coagulation in prostate cancer-associated thrombosis. Blood, 2015, 126, 1379-1389.	1.4	117
174	Concurrent deletion of 16q23 and PTEN is an independent prognostic feature in prostate cancer. International Journal of Cancer, 2015, 137, 2354-2363.	5.1	39
175	Partial PTEN deletion is linked to poor prognosis in breast cancer. BMC Cancer, 2015, 15, 963.	2.6	30
176	Cdc7 overexpression is an independent prognostic marker and a potential therapeutic target in colorectal cancer. Diagnostic Pathology, 2015, 10, 125.	2.0	25
177	Loss of SOX9 Expression Is Associated with PSA Recurrence in ERG-Positive and PTEN Deleted Prostate Cancers. PLoS ONE, 2015, 10, e0128525.	2.5	26
178	High-Level HOOK3 Expression Is an Independent Predictor of Poor Prognosis Associated with Genomic Instability in Prostate Cancer. PLoS ONE, 2015, 10, e0134614.	2.5	16
179	HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy. Oncotarget, 2015, 6, 12822-12834.	1.8	34
180	Heterogeneity in D×³Amico classificationâ€“based low-risk prostate cancer: Differences in upgrading and upstaging according to active surveillance eligibility. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 329.e13-329.e19.	1.6	37

#	Article	IF	Citations
181	Determination of Tumor Heterogeneity in Colorectal Cancers Using Heterogeneity Tissue Microarrays. Pathology and Oncology Research, 2015, 21, 1183-1189.	1.9	8
182	Prevalence of chromosomal rearrangements involving non-ETS genes in prostate cancer. International Journal of Oncology, 2015, 46, 1637-1642.	3.3	13
183	Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion. Oncology Reports, 2015, 34, 1211-1220.	2.6	12
184	Reprogramming of the ERRÎ± and ERÎ± Target Gene Landscape Triggers Tamoxifen Resistance in Breast Cancer. Cancer Research, 2015, 75, 720-731.	0.9	36
185	Î²III-tubulin overexpression is linked to aggressive tumor features and shortened survival in clear cell renal cell carcinoma. World Journal of Urology, 2015, 33, 1561-1569.	2.2	14
186	Heterogeneity of amplification of HER2, EGFR, CCND1 and MYC in gastric cancer. BMC Gastroenterology, 2015, 15, 7.	2.0	101
187	VEGFR-1 Overexpression Identifies a Small Subgroup of Aggressive Prostate Cancers in Patients Treated by Prostatectomy. International Journal of Molecular Sciences, 2015, 16, 8591-8606.	4.1	4
188	HDAC1 overexpression independently predicts biochemical recurrence and is associated with rapid tumor cell proliferation and genomic instability in prostate cancer. Experimental and Molecular Pathology, 2015, 98, 419-426.	2.1	26
189	Saccharomyces cerevisiaeâ€“like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusionâ€“positive and fusion-negative cancers. Human Pathology, 2015, 46, 514-523.	2.0	10
190	Î²III-tubulin overexpression is linked to left-sided tumor localization and nuclear Î²-catenin expression in colorectal cancer. Cancer Treatment Communications, 2015, 4, 96-102.	0.4	0
191	The prognostic value of SUMO1/Sentrin specific peptidase 1 (SENP1) in prostate cancer is limited to ERG-fusion positive tumors lacking PTEN deletion. BMC Cancer, 2015, 15, 538.	2.6	30
192	Cytoplasmic Accumulation of Sequestosome 1 (p62) Is a Predictor of Biochemical Recurrence, Rapid Tumor Cell Proliferation, and Genomic Instability in Prostate Cancer. Clinical Cancer Research, 2015, 21, 3471-3479.	7.0	43
193	The Aging Prostate Is Never â€œNormalâ€• Implications from the Genomic Characterization of Multifocal Prostate Cancers. European Urology, 2015, 68, 348-350.	1.9	5
194	Does the extent of variant histology affect oncological outcomes in patients with urothelial carcinoma of the bladder treated with radical cystectomy?. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 21.e1-21.e9.	1.6	48
195	BAZ2A (TIP5) is involved in epigenetic alterations in prostate cancer and its overexpression predicts disease recurrence. Nature Genetics, 2015, 47, 22-30.	21.4	141
196	FGFR1 Amplification Is Often Homogeneous and Strongly Linked to the Squamous Cell Carcinoma Subtype in Esophageal Carcinoma. PLoS ONE, 2015, 10, e0141867.	2.5	16
197	Overexpression of thymidylate synthase (TYMS) is associated with aggressive tumor features and early PSA recurrence in prostate cancer. Oncotarget, 2015, 6, 8377-8387.	1.8	44
198	Genomic deletion of chromosome 12p is an independent prognostic marker in prostate cancer. Oncotarget, 2015, 6, 27966-27979.	1.8	30

#	Article	IF	Citations
199	The combination of DNA ploidy status and PTEN/6q15 deletions to provide strong and independent prognostic information in prostate cancer.. Journal of Clinical Oncology, 2015, 33, 5027-5027.	1.6	0
200	Long-term follow-up of bone marrow micrometastases in colon cancer patients.. Journal of Clinical Oncology, 2015, 33, 3529-3529.	1.6	0
201	Loss of Somatostatin Receptor Subtype 2 in Prostate Cancer Is Linked to an Aggressive Cancer Phenotype, High Tumor Cell Proliferation and Predicts Early Metastatic and Biochemical Relapse. PLoS ONE, 2014, 9, e100469.	2.5	20
202	Heterogeneity and chronology of PTEN deletion and ERG fusion in prostate cancer. Modern Pathology, 2014, 27, 1612-1620.	5.5	69
203	Clinical significance of different types ofp53gene alteration in surgically treated prostate cancer. International Journal of Cancer, 2014, 135, 1369-1380.	5.1	95
204	Qualitative and Quantitative Requirements for Assessing Prognostic Markers in Prostate Cancer. Microarrays (Basel, Switzerland), 2014, 3, 137-158.	1.4	2
205	Î²III-Tubulin Overexpression Is an Independent Predictor of Prostate Cancer Progression Tightly Linked to ERG Fusion Status and PTEN Deletion. American Journal of Pathology, 2014, 184, 609-617.	3.8	48
206	High RNA-binding motif protein 3 expression is an independent prognostic marker in operated prostate cancer and tightly linked to ERG activation and PTEN deletions. European Journal of Cancer, 2014, 50, 852-861.	2.8	34
207	TMPRSS2-ERG Fusions Are Strongly Linked to Young Patient Age in Low-grade Prostate Cancer. European Urology, 2014, 66, 978-981.	1.9	54
208	Activated leukocyte cell adhesion molecule (ALCAM/CD166) expression in head and neck squamous cell carcinoma (HNSSC). Pathology Research and Practice, 2014, 210, 649-655.	2.3	11
209	Intratumor DNA Methylation Heterogeneity Reflects Clonal Evolution in Aggressive Prostate Cancer. Cell Reports, 2014, 8, 798-806.	6.4	219
210	Reduced membranous MET expression is linked to bladder cancer progression. Cancer Genetics, 2014, 207, 147-152.	0.4	5
211	A Tertiary Gleason Pattern in the Prostatectomy Specimen and its Association with Adverse Outcome after Radical Prostatectomy. Journal of Urology, 2014, 192, 97-102.	0.4	34
212	Patterns of TPD52 overexpression in multiple human solid tumor types analyzed by quantitative PCR. International Journal of Oncology, 2014, 44, 609-615.	3.3	48
213	Loss of ALCAM expression is linked to adverse phenotype and poor prognosis in breast cancer: A TMA-based immunohistochemical study on 2,197 breast cancer patients. Oncology Reports, 2014, 32, 2628-2634.	2.6	22
214	Concomitant mutation and amplification of the ERBB2 (HER2) gene in human tumors.. Journal of Clinical Oncology, 2014, 32, 11071-11071.	1.6	2
215	Prognostic value of alpha-methyl CoA racemase (AMACR) expression in renal cell carcinoma. World Journal of Urology, 2013, 31, 847-853.	2.2	13
216	Value of cell cycle progression (CCP) score to predict biochemical recurrence and definitive post-surgical pathology.. Journal of Clinical Oncology, 2013, 31, 5043-5043.	1.6	2

#	Article	IF	Citations
217	Epidermal growth factor receptor (EGFR) in salivary gland carcinomas: Potentials as therapeutic target. Oral Oncology, 2012, 48, 991-996.	1.5	31
218	Genomic Deletion of PTEN Is Associated with Tumor Progression and Early PSA Recurrence in ERG Fusion-Positive and Fusion-Negative Prostate Cancer. American Journal of Pathology, 2012, 181, 401-412.	3.8	278
219	Estrogen receptor alpha (ESR1) gene amplification status and clinical outcome in tamoxifen-treated postmenopausal patients with endocrine-responsive early breast cancer: An analysis of the prospective ABCSG-6 trial.. Journal of Clinical Oncology, 2012, 30, 10501-10501.	1.6	3
220	Association of nuclear accumulation of p53 with ERG fusion and poor prognosis in prostate cancer.. Journal of Clinical Oncology, 2012, 30, 124-124.	1.6	0
221	Reply to A. Italiano. Journal of Clinical Oncology, 2011, 29, 4718-4719.	1.6	11
222	Reply to R. Simon. Journal of Clinical Oncology, 2011, 29, 2941-2944.	1.6	0
223	Reply to V. Arena et al. Journal of Clinical Oncology, 2009, 27, e9-e10.	1.6	3
224	Tissue microarrays for comparing molecular features with proliferation activity in breast cancer. International Journal of Cancer, 2006, 118, 2190-2194.	5.1	100
225	Tissue microarrays. , 2005, , .		0
226	Changes in Cytoskeletal Protein Composition Indicative of an Epithelial-Mesenchymal Transition in Human Micrometastatic and Primary Breast Carcinoma Cells. Clinical Cancer Research, 2005, 11, 8006-8014.	7.0	277
227	Tissue microarrays for early target evaluation. Drug Discovery Today: Technologies, 2004, 1, 41-48.	4.0	10
228	Prognostic Molecular Features in Diffuse Large B-Cell Lymphoma from Saudi Arabia.. Blood, 2004, 104, 4609-4609.	1.4	0
229	Epstein-Barr Virus Infection Is Not the Sole Cause of High Prevalence for Hodgkinâ€™s Lymphoma in Saudi Arabia.. Blood, 2004, 104, 3120-3120.	1.4	0
230	Tissue microarrays in drug discovery. Nature Reviews Drug Discovery, 2003, 2, 962-972.	46.4	178
231	CDKN2A Mutation Analysis, Protein Expression, and Deletion Mapping of Chromosome 9p in Conventional Clear-Cell Renal Carcinomas. American Journal of Pathology, 2001, 158, 593-601.	3.8	46
232	CGH, cDNA and Tissue Microarray Analyses ImplicateFGFR2Amplification in a Small Subset of Breast Tumors. Analytical Cellular Pathology, 2001, 22, 229-234.	2.1	60
233	Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughputin situ studies. Journal of Pathology, 2001, 195, 72-79.	4.5	355
234	Improved procedure for fluorescence in situ hybridization on tissue microarrays. Cytometry, 2001, 45, 83-86.	1.8	60

#	Article	IF	Citations
235	Microarrays of bladder cancer tissue are highly representative of proliferation index and histological grade. Journal of Pathology, 2001, 194, 349-357.	4.5	274
236	Discovery of new DNA amplification loci in prostate cancer by comparative genomic hybridization. Prostate, 2001, 46, 184-190.	2.3	76
237	Tissue microarrays (TMAs) for high-throughput molecular pathology research. International Journal of Cancer, 2001, 94, 1-5.	5.1	220
238	Marked genetic similarities between hepatitis B virus-positive and hepatitis C virus-positive hepatocellular carcinomas. Journal of Pathology, 2000, 192, 307-312.	4.5	58
239	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	424
240	Prognostic utility of the recently recommended histologic classification and revised TNM staging system of renal cell carcinoma. Cancer, 2000, 89, 604-614.	4.1	2
241	Cyclin D1 overexpression lacks prognostic significance in superficial urinary bladder cancer. Journal of Pathology, 1999, 188, 44-50.	4.5	45
242	Chromosomal imbalances in small cell carcinomas of the urinary bladder. , 1999, 189, 230-235.		50
243	Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nature Medicine, 1998, 4, 844-847.	30.7	3,661
244	Carcinomas of the renal pelvis associated with smoking and phenacetin abuse:p53 mutations and polymorphism of carcinogen-metabolising enzymes. , 1998, 79, 531-536.		27
245	EGF-r gene copy number changes in renal cell carcinoma detected by fluorescencein situ hybridization. , 1998, 184, 424-429.		52
246	Pussycats and baby tigers: non-invasive (pTa) and minimally invasive (pT1) bladder carcinomas are not the same!. , 1998, 185, 339-341.		34
247	Comparative genomic hybridization reveals frequent chromosome 13q and 4q losses in renal carcinomas with sarcomatoid transformation. , 1998, 185, 382-388.		41
248	FOCAL NEUROENDOCRINE DIFFERENTIATION LACKS PROGNOSTIC SIGNIFICANCE IN PROSTATE CORE NEEDLE BIOPSIES. Journal of Urology, 1998, 160, 406-410.	0.4	55
249	AIB1, a Steroid Receptor Coactivator Amplified in Breast and Ovarian Cancer. Science, 1997, 277, 965-968.	12.6	1,514
250	DNA Aneuploidy, S-phase fraction, nuclear p53 positivity, and survival in non-small-cell lung carcinoma. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 1997, 431, 173-179.	2.8	19
251	Ki67 LABELLING INDEX: AN INDEPENDENT PREDICTOR OF PROGRESSION IN PROSTATE CANCER TREATED BY RADICAL PROSTATECTOMY. Journal of Pathology, 1996, 178, 437-441.	4.5	174
252	Chromosome-9 loss detected by fluorescencein situ hybridization in bladder cancer. International Journal of Cancer, 1995, 64, 99-103.	5.1	61

#	Article	IF	Citations
253	Heterogeneity of chromosome 17 and erbB-2 gene copy number in primary and metastatic bladder cancer. Cytometry, 1995, 21, 40-46.	1.8	36